ScreenerHero

NCEL NewcelX Ltd.

NAS · US · Healthcare · Biotechnology · newcelx.com
3.035USD+2.51%Mkt Cap: 17.53M $P/E: 5.62

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap17.53M USD
Enterprise Value15.63M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.30M USD
Revenue/Share—
Last Price3.035 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)5.62
P/E (Forward)-4.93
PEG—
EV/EBITDA-3.93
EV/Revenue—
P/S—
P/B2.64
EPS (TTM)0.52
EPS (Forward)-0.60
52W Range
1.8306% of range22.40
52W High22.40 USD
52W Low1.830 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-114.48%
ROA-72.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.77M USD
CapEx (TTM)8.00K USD
FCF Margin—
FCF Yield-70.27%
Net Debt-318.00K USD
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.05
Current Ratio0.40
Quick Ratio0.21
Book Value/Sh1.12 USD
Cash/Share0.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateOct 31, 2025
Analyst Consensus
Rating—
Target (Mean)23.00 USD
Upside (mean)+657.8%
Target Range23.00 USD – 23.00 USD
# Analysts1
Ownership
Shares Out.5.78M
Float2.50M
Insiders65.58%
Institutions0.23%
Short Interest
Short Ratio1.9d
Short % Out.0.26%
Shares Short15.02K
Short (prev mo.)36.95K
Technical
SMA 503.266 (-7.1%)
SMA 2003.065 (-1.0%)
Beta—
S&P 52W Chg15.78%
Avg Vol (30d)5.89K
Avg Vol (10d)4.83K
Technical Indicators
RSI (14)47.1
MACD-0.1070
MACD Signal-0.1159
MACD Hist.+0.0089
BB Upper3.414 USD
BB Middle3.061 USD
BB Lower2.707 USD
BB Width23.11%
ATR (14)0.2167 USD
Vol Ratio (20d)0.29x